Avance Clinical at BIO-Europe 2026 | Early-Phase CRO

Yes. Avance Clinical is exhibiting at BIO-Europe 2026, 9-11 November 2026, at Koelnmesse in Cologne, Germany, at Booth #8-24.

Biotechs can meet with Avance Clinical at BIO-Europe 2026 to discuss early-phase strategy, first-in-human and proof-of-concept planning, and pathways from Europe into Australia and broader multi-regional development.

Avance Clinical pairs Australia’s early-phase advantages, including data accepted by the FDA and EMA, with a GlobalReady model spanning Australia, Asia-Pacific, China, North America, and Europe. European sponsors get one CRO across every region their program will touch.

Australia doesn’t require an IND, so biotechs can start Phase I without waiting on one, saving up to a year in regulatory processing time plus real cost. Overall study start-up runs 5-6 weeks from final protocol to approval, and separately, clients are currently seeing ethics committee (IRB/EC) turnaround of around 3 weeks. Biotechs can also access government rebates of up to 43.5% on eligible R&D spend, backed by a network of investigators and clinical sites across Australia and New Zealand.

Avance Clinical’s therapeutic Centers of Excellence include Renal & Metabolic, CNS, and Oncology, with additional experience in Rare Disease and infectious disease programs, spanning more than 250 therapeutic indications.